Healthcare Industry News: Endoscopic Surgery
News Release - April 29, 2009
Starch Medical Launches Advanced Laparoscopic Hemostat
SAN JOSE, Calif., April 29 -- (Healthcare Sales & Marketing Network) -- Starch Medical Inc (SMI), a San Jose, CA-based medical device manufacturer, announces the introduction of its advanced PerClot(TM) Laparoscopic hemostat in the European Union and other major international markets. PerClot(TM) Laparoscopic, a delivery configuration within the PerClot(TM) Polysaccharide Hemostatic System (PHS), was awarded CE approval in 2008. Perclot(TM) Laparoscopic is a hemostatic system designed for applications in minimally invasive surgical procedures.The PerClot(TM) Laparoscopic system contains a unique instrument for precise delivery of AMP(TM) particles through the laparoscope to the bleeding site. The delivery instrument is easily attached to the PerClot(TM) bellows dispenser and enables hemostat delivery under direct vision to the wound site for the control of capillary, venous and arterial bleeding. The PerClot(TM) laparoscopic instrument can be employed in the working channel of a standard laparoscope for the delivery of AMP(TM) particles.
Absorbable Modified Polymer (AMP(TM)) technology is a sophisticated, proprietary engineering process that modifies plant starch into ultra-hydrophilic, adhesive forming hemostatic polymers. AMP(TM) materials are biocompatible, absorbable polysaccharides containing no animal or human components.
David Lang, President of SMI, commented, "The clinical introduction of PerClot(TM) Laparoscopic and its proprietary, integrated AMP(TM) technology represents a unique advancement in hemostatic delivery. The company is pleased to offer surgeons a delivery option which will enhance the control of bleeding in the expanding practice of minimally invasive surgery. The performance features of PerClot(TM) Laparoscopic were favorably received in pre-introduction evaluations in Europe, Asia and Latin America. Additional clinical studies will be conducted at key medical centers in Europe."
PerClot(TM) Laparoscopic, as well as other customized, minimally invasive instruments under development, will be displayed at the 17th International Congress of the European Association for Endoscopic Surgery (www.eaes-eur.org) in Prague, Czech Republic in June, 2009.
SMI is a privately-held medical device company engaged in the design, manufacture, marketing and licensing of breakthrough, hemostatic solutions. SMI's proprietary, patent-pending technology platform (AMP(TM)), including powders, foams and films, will focus on the worldwide, multi-billion dollar biomaterial, hemostasis, and wound care marketplace. For additional information, distribution inquiries, and licensing options, please visit www.starchmedical.com.
Source: Starch Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.